ASCO: Conversational AI tackles missed colonoscopies
An artificial intelligence-based tool has shown impressive results in raising colorectal cancer screening rates in underserved populations.
Newsletters and Deep Dive digital magazine
An artificial intelligence-based tool has shown impressive results in raising colorectal cancer screening rates in underserved populations.
Gilead Sciences’ bid to extend the uses of TROP2-directed Trodelvy into lung cancer currently rests on the results of its EVOKE-01 study, revealed for the first time at th
Novartis’ first-in-class STAMP inhibitor Scemblix could be headed for use earlier in the treatment pathway for chronic myeloid leukaemia (CML).
The US FDA has started a fresh review of Astellas' zolbetuximab, trying to become the first claudin (CLDN) 18.2-targeting drug to reach the US market, after turning it dow
Gilead Sciences' TROP2-directed drug Trodelvy has missed the target in another clinical trial, this time in urothelial carcinoma, the most common form of bladder cancer.
Editor's Picks
Newsletters and Deep Dive
digital magazine